HSP110通过稳定MyD88维持活化B细胞弥漫大B细胞淋巴瘤的慢性NF-κB信号
研究在活化B细胞弥漫大B细胞淋巴瘤(ABC-DLBCL)细胞系中发现,短发夹RNA沉默HSP110可降低细胞存活、减少IgM-MyD88共定位及NF-κB信号;过表达HSP110则增强NF-κB信号。HSP110与野生型及MyD88 L265P相互作用并稳定二者,对MyD88 L265P稳定作用更强。患者淋巴结活检中HSP110表达高于正常反应性淋巴结,且与MyD88水平强相关。
要点
- 沉默HSP110降低ABC-DLBCL细胞系存活并减弱NF-κB信号
- HSP110与野生型MyD88及MyD88 L265P相互作用并稳定二者
- HSP110对MyD88 L265P的稳定作用强于野生型MyD88
核心结论
- HSP110通过稳定MyD88调控ABC-DLBCL中的NF-κB信号,是潜在治疗靶点。
研究设计与样本
- 研究采用ABC-DLBCL细胞系及非DLBCL细胞系进行体外实验,并使用患者淋巴结活检标本比较表达。
主要发现
- 短发夹RNA介导的HSP110沉默降低多种ABC-DLBCL细胞系的存活,并减少免疫球蛋白M-MyD88共定位及后续NF-κB信号。
- 在ABC-DLBCL或非DLBCL细胞系中过表达HSP110增加NF-κB信号。
- 免疫沉淀和邻近连接实验显示HSP110与野生型MyD88及MyD88 L265P均存在相互作用。
- HSP110稳定野生型MyD88和MyD88 L265P两种形式,对MyD88 L265P的稳定作用更强。
- ABC-DLBCL患者淋巴结活检中HSP110表达高于正常反应性淋巴结,且HSP110水平与MyD88水平呈强相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive lymphoproliferative disorder involving chronic NF-κB activation. Several mutations in the BCR and MyD88 signaling pathway components, such as MyD88 L265P, are implicated in this aberrant activation. Among heat shock proteins, HSP110 has recently been identified as a prosurvival and/or proliferation factor in many cancers, but its role in ABC-DLBCL survival mechanisms remained to be established. We observed that short hairpin RNA-mediated HSP110 silencing decreased the survival of several ABC-DLBCL cell lines and decreased immunoglobulin M-MyD88 co-localization and subsequent NF-κB signaling. Conversely, overexpression of HSP110 in ABC-DLBCL or non-DLBCL cell lines increased NF-κB signaling, indicating a tight interplay between HSP110 and the NF-κB pathway. By using immunoprecipitation and proximity ligation assays, we identified an interaction between HSP110 and both wild-type MyD88 and MyD88 L265P. HSP110 stabilized both MyD88 forms with a stronger effect on MyD88 L265P, thus facilitating chronic NF-κB activation. Finally, HSP110 expression was higher in lymph node biopsies from patients with ABC-DLBCL than in normal reactive lymph nodes, and a strong correlation was found between the level of HSP110 and MyD88. In conclusion, we identified HSP110 as a regulator of NF-κB signaling through MyD88 stabilization in ABC-DLBCL. This finding reveals HSP110 as a new potential therapeutic target in ABC-DLBCL.
引用
- Boudesco C, Verhoeyen E, Martin L, et al. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood. 2018. PMID: 29871863. doi:10.1182/blood-2017-12-819706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。